EMEA-003077-PIP01-21
Table of contents
Key facts
Invented name |
COVID-19 Vaccine (inactivated, adjuvanted) Valneva
|
Active substance |
SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)
|
Therapeutic area |
Vaccines
|
Decision number |
P/0184/2022
|
PIP number |
EMEA-003077-PIP01-21
|
Pharmaceutical form(s) |
Suspension for injection
|
Condition(s) / indication(s) |
Prevention of Coronavirus disease 2019 (COVID-19)
|
Route(s) of administration |
Intramuscular use
|
Contact for public enquiries |
Valneva Austria GmbH
E-mail: medinfo@valneva.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|